中国科学院机构知识库网格
Chinese Academy of Sciences Institutional Repositories Grid
首页 机构 成果 学者
  
  1. CAS IR Grid
  2. 上海药物研究所
  3. 中国科学院上海药物研究所
  4. 新药研究国家重点实验室
Licochalcone A suppresses the proliferation of sarcoma HT-1080 cells, as a selective R132C mutant IDH1 inhibitor

文献类型：期刊论文

作者Hu, Chujiao2; Zuo, Yu1; Liu, Jingqiu3; Xu, Heng3; Liao, Weike2; Dang, Yongjun4; Luo, Cheng3; Tang, Lei2; Zhang, Hao3
刊名BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
出版日期2020-01-15
卷号30期号:2页码:5
关键词Licochalcone A Mutant IDH1 Selective inhibitor
ISSN号0960-894X
DOI10.1016/j.bmcl.2019.126825
通讯作者Tang, Lei(tlei1974@163.com) ; Zhang, Hao(hao_cadd@simm.ac.cn)
英文摘要IDH1 mutations are closely related to the development and progression of various human cancers, such as glioblastoma, sarcoma, and acute myeloid leukemia. By screening dozens of reported natural compounds using both wild-type and mutant IDH1 enzymatic assays, we discovered Licochalcone A is a selective inhibitor to the R132C-mutant IDH1 with an IC50 value of 5.176 mu M, and inhibits the proliferation of sarcoma HT-1080 cells with an IC50 value of 10.75 mu M. Suggested by the molecular docking results, Licochalcone A might occupy the allosteric pocket between the two monomers of IDH1 homodimer, and the R132H mutation was unfavorable for the binding of Licochalcone A with the IDH1 protein, as compared to the R132C mutation. Revealed by the RNA-Seq data analysis, the Cell Cycle pathway was the most over-represented pathway for HT-1080 cells treated with Licochalcone A. Consistent with these results, Licochalcone A induced apoptosis and cell cycle arrest of HT-1080 cells, while it showed minimal effect against the proliferation of normal RCTEC cells. The discovery of Licochalcone A as a mutation-selective IDH1 inhibitor can serve as a promising starting point for the development of mutation-selective anti-tumor lead compounds targeting IDH1.
WOS关键词GANODERMA-LUCIDUM ; MUTATIONS
资助项目National Natural Science Foundation of China[81625022] ; National Natural Science Foundation of China[91853205] ; Institutes for Drug Discovery and Development, Chinese Academy of Sciences[CASIMM0120184015] ; National-Local Joint Engineering Research Center for Innovative & Generic Chemical Drug, Guizhou High-level Innovative Talents Supporting Program[2016-4015] ; Shanghai Young Science and Technology Talents Sailing Plan[19YF1457200]
WOS研究方向Pharmacology & Pharmacy ; Chemistry
语种英语
WOS记录号WOS:000504873300027
出版者PERGAMON-ELSEVIER SCIENCE LTD
源URL[http://119.78.100.183/handle/2S10ELR8/282345]  
专题新药研究国家重点实验室
通讯作者Tang, Lei; Zhang, Hao
作者单位1.Nanchang Univ, Sch Pharm, Nanchang 330006, Jiangxi, Peoples R China
2.Guizhou Medcial Univ, State Key Lab Funct & Applicat Med Plants, Guiyang 550014, Guizhou, Peoples R China
3.Chinese Acad Sci, Drug Discovery & Design Ctr, Shanghai Inst Mat Med, State Key Lab Drug Res, Shanghai 201203, Peoples R China
4.Fudan Univ, Sch Basic Med Sci, Shanghai 200032, Peoples R China
推荐引用方式
GB/T 7714		 Hu, Chujiao,Zuo, Yu,Liu, Jingqiu,et al. Licochalcone A suppresses the proliferation of sarcoma HT-1080 cells, as a selective R132C mutant IDH1 inhibitor[J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,2020,30(2):5.
APA Hu, Chujiao.,Zuo, Yu.,Liu, Jingqiu.,Xu, Heng.,Liao, Weike.,...&Zhang, Hao.(2020).Licochalcone A suppresses the proliferation of sarcoma HT-1080 cells, as a selective R132C mutant IDH1 inhibitor.BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,30(2),5.
MLA Hu, Chujiao,et al."Licochalcone A suppresses the proliferation of sarcoma HT-1080 cells, as a selective R132C mutant IDH1 inhibitor".BIOORGANIC & MEDICINAL CHEMISTRY LETTERS 30.2(2020):5.

入库方式： OAI收割

来源：上海药物研究所

浏览0
下载0
收藏0
其他版本

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。